iguratimod has been researched along with leucine methyl ester in 1 studies
| Studies (iguratimod) | Trials (iguratimod) | Recent Studies (post-2010) (iguratimod) | Studies (leucine methyl ester) | Trials (leucine methyl ester) | Recent Studies (post-2010) (leucine methyl ester) |
|---|---|---|---|---|---|
| 134 | 19 | 109 | 106 | 0 | 7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, S; Inoue, T; Ito, K; Iwata, M; Nagai, T; Nishioka, Y; Sato, T; Sawada, T; Tohma, S; Yamamoto, K | 1 |
1 other study(ies) available for iguratimod and leucine methyl ester
| Article | Year |
|---|---|
Inhibition of L-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Cell Death; Dipeptides; Growth Inhibitors; Humans; Hydrogen-Ion Concentration; Leucine; Lysosomes; Monocytes; Phenylmethylsulfonyl Fluoride; Sulfonamides; Tumor Cells, Cultured; U937 Cells | 2000 |